Spyre Therapeutics, Inc. (SYRE) Operating income 2016–2025
Spyre Therapeutics, Inc. (SYRE) annual operating income history from SEC filings — each fiscal year as reported.
-$209.6MFY2025 · since FY2016: -$21.9M → -$209.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$209.6M | -0.5% |
| FY2024 | -$208.6M | +13.9% |
| FY2023 | -$242.3M | -185.8% |
| FY2022 | -$84.8M | -29.1% |
| FY2021 | -$65.6M | +19.4% |
| FY2020 | -$81.5M | -1.4% |
| FY2019 | -$80.3M | -76.7% |
| FY2018 | -$45.5M | -64.3% |
| FY2017 | -$27.7M | -26.3% |
| FY2016 | -$21.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice